Bioline RX Ltd Sponsored ADR (YP2) Ratios
Bioline RX Ltd Sponsored ADR Ratios
DE:YP2's free cash flow for Q2 2026 was $-3.26M. For the 2026 fiscal year, DE:YP2's free cash flow was increased by $5.98K and operating cash flow was $-3.26M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.95 | 1.76 | 1.10 | 4.87 | 5.91 |
| Quick Ratio | 1.78 | 1.56 | 1.06 | 4.85 | 5.89 |
| Cash Ratio | 0.27 | 0.68 | 0.10 | 0.99 | 1.34 |
| Solvency Ratio | -0.04 | -0.20 | -1.17 | -0.95 | -1.98 |
| Operating Cash Flow Ratio | -0.67 | -2.85 | -0.53 | -2.46 | -2.43 |
| Short-Term Operating Cash Flow Coverage | -1.73 | -9.80 | -7.19 | -17.02 | -8.55 |
| Net Current Asset Value | $ 6.12M | $ 1.66M | $ -3.52M | $ 26.46M | $ 44.10M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.25 | 0.39 | 0.18 | 0.16 | 0.06 |
| Debt-to-Equity Ratio | 0.56 | 1.12 | 0.88 | 0.24 | 0.07 |
| Debt-to-Capital Ratio | 0.36 | 0.53 | 0.47 | 0.20 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.20 | 0.40 | 0.33 | 0.15 | 0.00 |
| Financial Leverage Ratio | 2.25 | 2.89 | 4.83 | 1.50 | 1.20 |
| Debt Service Coverage Ratio | -0.04 | 0.29 | -10.74 | -7.70 | -6.44 |
| Interest Coverage Ratio | -8.04 | -2.23 | -22.91 | -13.51 | -25.18 |
| Debt to Market Cap | 0.81 | 0.02 | 0.00 | 0.01 | 0.00 |
| Interest Debt Per Share | 2.78 | 0.30 | 0.21 | 0.28 | 0.13 |
| Net Debt to EBITDA | -30.70 | 1.18 | -0.13 | -0.06 | 0.35 |
| Profitability Margins | |||||
| Gross Profit Margin | 36.19% | 67.99% | 23.08% | 0.00% | 0.00% |
| EBIT Margin | -63.22% | -0.51% | -1218.13% | 0.00% | 0.00% |
| EBITDA Margin | -18.90% | 13.54% | -1189.29% | 0.00% | 0.00% |
| Operating Profit Margin | -871.78% | -70.52% | -1035.29% | 0.00% | 0.00% |
| Pretax Profit Margin | -171.70% | -31.86% | -1262.79% | 0.00% | 0.00% |
| Net Profit Margin | -99.58% | -31.86% | -1262.79% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -171.70% | -31.86% | -1262.79% | 0.00% | 0.00% |
| Net Income Per EBT | 58.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 19.69% | 45.18% | 121.97% | 85.57% | 109.19% |
| Return on Assets (ROA) | -2.90% | -23.70% | -94.82% | -32.67% | -33.24% |
| Return on Equity (ROE) | -6.51% | -68.50% | -458.40% | -49.08% | -39.73% |
| Return on Capital Employed (ROCE) | -36.03% | -86.84% | -235.06% | -44.38% | -34.57% |
| Return on Invested Capital (ROIC) | -30.96% | -71.60% | -200.27% | -43.08% | -33.21% |
| Return on Tangible Assets | -4.83% | -32.40% | -123.52% | -45.78% | -45.33% |
| Earnings Yield | -10.41% | -1.35% | -1.50% | -2.05% | -0.75% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.61 | 7.49 | 6.78 | 0.00 | 0.00 |
| Payables Turnover | 0.22 | 1.66 | 0.34 | 0.00 | 0.00 |
| Inventory Turnover | 0.35 | 2.95 | 1.89 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.39 | 21.39 | 2.54 | 0.00 | 0.00 |
| Asset Turnover | 0.03 | 0.74 | 0.08 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.10 | 3.60 | 0.21 | 0.00 | 0.00 |
| Cash Conversion Cycle | -506.88 | -47.35 | -827.62 | 0.00 | 0.00 |
| Days of Sales Outstanding | 139.94 | 48.72 | 53.84 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 1032.98 | 123.93 | 193.08 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1679.80 | 219.99 | 1074.54 | 0.00 | 0.00 |
| Operating Cycle | 1172.92 | 172.65 | 246.92 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.98 | -0.55 | -0.35 | -0.51 | -0.53 |
| Free Cash Flow Per Share | -1.99 | -0.55 | -0.36 | -0.51 | -0.54 |
| Dividend Paid and CapEx Coverage Ratio | -322.94 | -812.46 | -76.12 | -83.04 | -243.02 |
| Capital Expenditure Coverage Ratio | -322.94 | -812.46 | -76.12 | -83.04 | -243.02 |
| Operating Cash Flow Coverage Ratio | -0.80 | -2.92 | -1.95 | -2.13 | -5.07 |
| Operating Cash Flow to Sales Ratio | -6.84 | -1.52 | -4.71 | 0.00 | 0.00 |
| Free Cash Flow Yield | -71.72% | -6.42% | -0.57% | -2.18% | -0.66% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -9.57 | -74.11 | -66.54 | -48.80 | -133.30 |
| Price-to-Sales (P/S) Ratio | 9.57 | 23.63 | 840.27 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.63 | 50.79 | 305.02 | 23.95 | 52.97 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.39 | -15.56 | -176.09 | -45.85 | -152.36 |
| Price-to-Operating Cash Flow Ratio | -1.40 | -15.58 | -178.40 | -46.41 | -152.99 |
| Price-to-Earnings Growth (PEG) Ratio | 0.10 | 0.84 | -0.70 | 2.32 | 2.02 |
| Enterprise Value Multiple | -81.33 | 175.68 | -70.78 | -42.78 | -149.46 |
| Enterprise Value | 18.28M | 688.32M | 4.04B | 1.22B | 3.60B |
| EV to EBITDA | -81.33 | 175.68 | -70.78 | -42.78 | -149.46 |
| EV to Sales | 15.37 | 23.78 | 841.80 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2.24 | -15.67 | -176.41 | -45.92 | -152.01 |
| EV to Operating Cash Flow | -2.25 | -15.69 | -178.73 | -46.47 | -152.63 |
| Tangible Book Value Per Share | 1.70 | 0.04 | -0.03 | 0.56 | 1.05 |
| Shareholders’ Equity Per Share | 4.43 | 0.17 | 0.21 | 0.99 | 1.54 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.29 | 0.36 | 0.07 | 0.00 | 0.00 |
| Net Income Per Share | -0.29 | -0.12 | -0.94 | -0.48 | -0.61 |
| Tax Burden | 0.58 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 2.72 | 62.73 | 1.04 | 0.86 | 1.09 |
| Research & Development to Revenue | 6.44 | 0.32 | 2.61 | 0.00 | 0.00 |
| SG&A to Revenue | 2.64 | 0.99 | 3.47 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.04 | 0.48 | 0.00 | 0.00 |
| Income Quality | 6.87 | 4.76 | 0.37 | 1.05 | 0.87 |
Currency in USD
